RA Capital Management LLC recently announced the acquisition of new stake in Orchard Therapeutics plc (NASDAQ:ORTX). The institutional investor has increased its shareholding in the Healthcare company by 0.37% to 10.4 million shares with purchase of 38529.0 shares. This fresh investment now brings its stake to 10.71% valued currently at $53.47 million. In addition, T. Rowe Price Associates, Inc. (I.. raised its holdings by 0.56 million to 4.91 million shares. And Artisan Partners LP has lifted its position by 13.97% or 0.35 million shares – to 2.84 million shares.

With over 16.67 million Orchard Therapeutics plc (ORTX) shares trading Tuesday and a closing price of $6.12 on the day, the dollar volume was approximately $102.02 million. The shares have shown a positive weekly performance of 27.50% and its price on 08/25/20 gained nearly 10.67%. Currently, there are 99.25M common shares owned by the public and among those 81.87M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for ORTX have a consensus price objective of $16.00. The analysts have set the share’s price value over the next 12 months at a high of $26.00 and a low of $9.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Orchard Therapeutics plc stock is 1.60 for the next 12 months. But an upside of 76.46% will see the stock hit the forecast high price target while mean target price for the stock is $15.00.

The top 3 mutual fund holders in Orchard Therapeutics plc are Federated Hermes Kaufmann Small C, T Rowe Price New Horizons Fund, and Artisan Small Cap Fund. Federated Hermes Kaufmann Small C owns 2.43 million shares of the company’s stock, all valued at over $12.5 million. The company bought an additional 0.43 million shares recently to bring their total holdings to about 2.50% of the shares outstanding. T Rowe Price New Horizons Fund bought 0.59 million shares to see its total holdings expand to 1.64 million shares valued at over $8.42 million and representing 1.69% of the shares outstanding. Artisan Small Cap Fund bought 0.29 million shares to bring its total holdings to over 1.63 million shares at a value of $8.36 million. Artisan Small Cap Fund now owns shares totaling to 1.67% of the shares outstanding.

Shares of Orchard Therapeutics plc (NASDAQ: ORTX) opened at $6.30, up $0.77 from a prior closing price of $5.53. However, the script later closed the day at $6.12, up 10.67%. The company’s stock has a 5-day price change of 27.50% and -36.84% over the past three months. ORTX shares are trading -55.49% year to date (YTD), with the 12-month market performance down to -55.72% lower. It has a 12-month low price of $4.44 and touched a high of $17.48 over the same period. Currently, 16.67 million shares have been traded, compared to an average intraday trading volume of 524.33K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.04%, 10.87%, and -36.95% respectively.

Institutional ownership of Orchard Therapeutics plc (NASDAQ: ORTX) shares accounts for 71.20% of the company’s 99.25M shares outstanding. Mutual fund holders own 16.25%, while other institutional holders and individual stakeholders account for 40.20% and — respectively.

It has a market capitalization of $598.47M. The earnings-per-share (ttm) stands at -$1.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.24% over the week and 8.02% over the month.

Analysts forecast that Orchard Therapeutics plc (ORTX) will achieve an EPS of -$0.45 for the current quarter, -$0.44 for the next quarter and -$1.78 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.52 while analysts give the company a high EPS estimate of -$0.38. Comparatively, EPS for the current quarter was -$0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 34.70%, and 5.30% over the next financial year.

Looking at the support for the ORTX, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on June 01, 2020, with the firm’s price target at. Guggenheim coverage for the Orchard Therapeutics plc (ORTX) stock in a research note released on September 17, 2019 offered a Buy rating with a price target of $31. Barclays was of a view on September 05, 2019 that the stock is Overweight, while Goldman gave the stock Buy rating on December 17, 2018, issuing a price target of. Wedbush on their part issued Outperform rating on November 26, 2018.